← Back to Search

Diagnostic Test

Total-Body PET Scan for Head and Neck Cancer

N/A

Waitlist Available

Led By Tokihiro Yamamoto, PhD

Research Sponsored by University of California, Davis

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up percent change from baseline to 2 hour post injection

Awards & highlights

Study Summary

This trial aims to study how a radioactive sugar behaves in head and neck cancer and inflammation over time using a world-first scanning device.

Who is the study for?

This trial is for adults over 18 with Stage II-IVa head and neck cancer who are set to receive radiation therapy. Participants must be able to lie still for up to an hour, give informed consent, follow the study schedule, and fast as required. It's not for those who've had prior radiation or chemo that overlaps with this treatment area, have severe claustrophobia, are pregnant or breastfeeding, prisoners, children under 18, weigh over 240 kg, or have a medical condition that could affect their safety in the study.Check my eligibility

What is being tested?

The trial is testing how a radioactive sugar (FDG) used in PET/CT scans behaves in patients immediately after injection and hours later using the EXPLORER total-body scanner. The aim is to improve response assessment of radiotherapy in head and neck cancers.See study design

What are the potential side effects?

Potential side effects may include discomfort from lying still during scanning and reactions related to fasting or the FDG injection such as allergic reactions or changes in blood sugar levels.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ percent change from baseline to 2 hour post injection

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~percent change from baseline to 2 hour post injection

This trial's timeline: 3 weeks for screening, Varies for treatment, and percent change from baseline to 2 hour post injection for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Utility of long-delayed FDG PET Imaging

Trial Design

1Treatment groups

Experimental Treatment

Group I: Total-body PET scanExperimental Treatment1 Intervention

All participants are asked to complete two study scan visits. First visit occurs before treatment and the second visit occurs 12 +/- 2 weeks after treatment. Each visit will involve a single injection of FDG, followed by three PET/CT scans that will start immediately following injection, at about 2 hours post-injection and at 5 hours post-injection, respectively and last about 60 minutes, 20 minutes and 20 minutes, respectively.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of California, DavisLead Sponsor

910 Previous Clinical Trials

4,706,979 Total Patients Enrolled

Colorado SPORE Developmental Research ProgramUNKNOWN

Tokihiro Yamamoto, PhDPrincipal InvestigatorUniversity of California, Davis

Media Library

Total Body PET/CT Imaging (Diagnostic Test) Clinical Trial Eligibility Overview. Trial Name: NCT05625217 — N/A

Head and Neck Cancers Research Study Groups: Total-body PET scan

Head and Neck Cancers Clinical Trial 2023: Total Body PET/CT Imaging Highlights & Side Effects. Trial Name: NCT05625217 — N/A

Total Body PET/CT Imaging (Diagnostic Test) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05625217 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any opportunities left for participants to join this trial?

"According to the clinicaltrials.gov database, this trial is not currently searching for participants. It was first posted on December 1st 2022 and last updated November 21st 2022. Nonetheless, there are 481 other trials seeking enrolment right now."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Total-Body FDG PET for Radiotherapy Response Assessment in Head and Neck Cancer

2023. "Total-Body FDG PET for Radiotherapy Response Assessment in Head and Neck Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05625217.